Comparative Pharmacology
Head-to-head clinical analysis: CARDIOLITE versus CARDIOTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIOLITE versus CARDIOTEC.
CARDIOLITE vs CARDIOTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium Tc-99m sestamibi is a lipophilic cation that accumulates in myocardial cells via passive diffusion across the sarcolemmal and mitochondrial membranes. Its uptake is proportional to myocardial blood flow and viability, allowing for imaging of myocardial perfusion.
CARDIOTEC is a technetium-99m labeled tracer that binds to viable myocardial cells. Its uptake is dependent on mitochondrial membrane potential and reflects myocardial perfusion and viability. The exact mechanism involves passive diffusion across cell membranes and retention within mitochondria via interaction with the mitochondrial complex I (NADH dehydrogenase).
CARDIOLITE (Technetium-99m sestamibi) is administered intravenously. For myocardial perfusion imaging, adult dose: 10-40 mCi (370-1480 MBq), administered as a single bolus.
220-260 MBq (6-7 mCi) intravenously as a single dose for planar or SPECT imaging.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; prolonged in elderly and renal impairment (up to 12-16 hours).
Terminal elimination half-life is 6-8 hours; clinically, steady-state achieved in 24-32 hours
Renal: 85-90% as unchanged drug; fecal: <5%
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical